Rapid Re-expansion of a Macroprolactinoma After Early Discontinuation of Bromocriptine
dc.contributor.author | Orrego, John J. | en_US |
dc.contributor.author | Chandler, William F. | en_US |
dc.contributor.author | Barkan, Ariel L. | en_US |
dc.date.accessioned | 2006-09-11T19:02:31Z | |
dc.date.available | 2006-09-11T19:02:31Z | |
dc.date.issued | 2000-11 | en_US |
dc.identifier.citation | Orrego, John J.; Chandler, William F.; Barkan, Ariel L.; (2000). "Rapid Re-expansion of a Macroprolactinoma After Early Discontinuation of Bromocriptine." Pituitary 3(3): 189-192. <http://hdl.handle.net/2027.42/47493> | en_US |
dc.identifier.issn | 1386-341X | en_US |
dc.identifier.issn | 1573-7403 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/47493 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=11383485&dopt=citation | en_US |
dc.description.abstract | Prolactin (PRL)-secreting pituitary adenomas are the most common functioning pituitary tumors. Medical treatment with dopamine agonists is the therapy of choice for macroprolactinomas (≥10 mm). Withdrawal of bromocriptine after weeks or months of uninterrupted therapy has been associated with rapid tumor re-expansion as evidenced by x-ray and CT scanning of the pituitary region. We report a patient with a giant macroprolactinoma who had a dramatic response to bromocriptine (tumor volume shrinkage of 53% within a month) but rapid re-expansion to its original dimensions one week after discontinuation of bromocriptine. To our knowledge, this is the first time that the rapid shrinkage/re-expansion of a macroprolactinoma has been documented with serial MRI scans. | en_US |
dc.format.extent | 91462 bytes | |
dc.format.extent | 3115 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.language.iso | en_US | |
dc.publisher | Kluwer Academic Publishers; Springer Science+Business Media | en_US |
dc.subject.other | Medicine & Public Health | en_US |
dc.subject.other | Diabetes | en_US |
dc.subject.other | Neurosurgery | en_US |
dc.subject.other | Hyperprolactinemia | en_US |
dc.subject.other | Prolactinoma | en_US |
dc.subject.other | Bromocriptine | en_US |
dc.subject.other | Pituitary Tumors | en_US |
dc.subject.other | Dopamine Agonists | en_US |
dc.title | Rapid Re-expansion of a Macroprolactinoma After Early Discontinuation of Bromocriptine | en_US |
dc.type | Article | en_US |
dc.subject.hlbsecondlevel | Public Health | en_US |
dc.subject.hlbsecondlevel | Internal Medicine and Specialties | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Section of Neurosurgery, Department of Surgery, Pituitary and Neuroendocrine Center, USA; Division of Endocrinology and Metabolism, Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationum | Section of Neurosurgery, Department of Surgery, Pituitary and Neuroendocrine Center, USA; Division of Endocrinology and Metabolism, Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationum | Section of Neurosurgery, Department of Surgery, Pituitary and Neuroendocrine Center, USA; Division of Endocrinology and Metabolism, Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationumcampus | Ann Arbor | en_US |
dc.identifier.pmid | 11383485 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/47493/1/11102_2004_Article_324060.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1023/A:1011412028660 | en_US |
dc.identifier.source | Pituitary | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.